Literature DB >> 29979653

Public biotech in 2017-the numbers.

Chris Morrison, Riku Lähteenmäki.   

Abstract

Year:  2018        PMID: 29979653     DOI: 10.1038/nbt.4175

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  4 in total

1.  Epic $12 billion deal and FDA's approval raise CAR-T to new heights.

Authors:  Elie Dolgin
Journal:  Nat Biotechnol       Date:  2017-10-11       Impact factor: 54.908

Review 2.  Tissue-agnostic cancer drug pipeline grows, despite doubts.

Authors:  Ken Garber
Journal:  Nat Rev Drug Discov       Date:  2018-03-09       Impact factor: 84.694

3.  Alnylam prepares to land first RNAi drug approval.

Authors:  Chris Morrison
Journal:  Nat Rev Drug Discov       Date:  2018-02-28       Impact factor: 84.694

4.  To keep biotechs trading at home, China pilots new stock market rules.

Authors:  Shannon Ellis
Journal:  Nat Biotechnol       Date:  2018-05-09       Impact factor: 54.908

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.